Tuesday, February 01, 2022 3:11:01 PM
Right so the process is Dr Linda Liau and others put the journal article together, NWBO reviews and checks off concerns and adds any comments about wording. Potential second draft gets put together then seen by NWBO again for further comments/approvals. In this process FDA guidance and opinion are taken into consideration and opinion about timing for submission gets discussed because endpoint analysis and validity of that analysis will be part of drawing any conclusions made about treatment effect in the article and must pass peer review, regulators actually being part of that group, as an informal prerequisite for formal approval by regulators such as FDA.
In the mean time, manufacturing issues are being dealt with so that positive data can be translated into a rapidly and widely available product soon after if not before actual formal approval which of course is supposed to be considered as kind of detached in significance from the journal article but in this case is very likely quite closely tied to it in several ways, especially as regards passing through a thorough peer review of a novel treatment approach in GBM but with platform implications for all solid tumor indications. Kind of a big deal where you want all the independent and semi independent moving parts to line up or you can pay a steep price.
If there is going to be a leak then it will come when the journal article gets submitted for review to the publisher or when info gets uploaded as to publishing date but I would suppose it’s “hackers and friends and family of reviewers beware”. I suspect trades in NWBO are being tracked very carefully right now. Now wouldn’t it be cool if those trades could be played back in slow motion?; ). Best wishes.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
Record Gold Prices Reshape Economics of New Mine Development • SNWGF • Mar 16, 2026 10:46 AM
Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • BLOZF • Mar 16, 2026 8:37 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
